KR20200045446A - 알츠하이머병의 치료를 위한 조성물 및 방법 - Google Patents

알츠하이머병의 치료를 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20200045446A
KR20200045446A KR1020197037319A KR20197037319A KR20200045446A KR 20200045446 A KR20200045446 A KR 20200045446A KR 1020197037319 A KR1020197037319 A KR 1020197037319A KR 20197037319 A KR20197037319 A KR 20197037319A KR 20200045446 A KR20200045446 A KR 20200045446A
Authority
KR
South Korea
Prior art keywords
ptpσ
therapeutic
therapeutic agent
app
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020197037319A
Other languages
English (en)
Korean (ko)
Inventor
잉지에 센
유안젱 구
제리 실버
브래들리 티. 랭
Original Assignee
케이스 웨스턴 리저브 유니버시티
오하이오 스테이트 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 케이스 웨스턴 리저브 유니버시티, 오하이오 스테이트 유니버시티 filed Critical 케이스 웨스턴 리저브 유니버시티
Publication of KR20200045446A publication Critical patent/KR20200045446A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1716—Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020197037319A 2017-06-05 2018-06-05 알츠하이머병의 치료를 위한 조성물 및 방법 Ceased KR20200045446A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762515272P 2017-06-05 2017-06-05
US62/515,272 2017-06-05
PCT/US2018/036116 WO2018226735A1 (en) 2017-06-05 2018-06-05 Compositions and methods for treating alzheimer's disease

Publications (1)

Publication Number Publication Date
KR20200045446A true KR20200045446A (ko) 2020-05-04

Family

ID=64567326

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197037319A Ceased KR20200045446A (ko) 2017-06-05 2018-06-05 알츠하이머병의 치료를 위한 조성물 및 방법

Country Status (8)

Country Link
US (1) US20200093890A1 (enExample)
EP (1) EP3634979A4 (enExample)
JP (1) JP2020524132A (enExample)
KR (1) KR20200045446A (enExample)
CN (1) CN110945011A (enExample)
AU (1) AU2018281330A1 (enExample)
CA (1) CA3064479A1 (enExample)
WO (1) WO2018226735A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120957751A (zh) * 2023-04-03 2025-11-14 神经再生制药公司 用于神经系统修复的蛋白酪氨酸磷酸酶楔形结构域肽二聚体
WO2025092748A1 (zh) * 2023-11-01 2025-05-08 拜西欧斯（北京）生物技术有限公司 多肽衍生物、其药物组合物及其用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083182A2 (en) * 2001-04-12 2002-10-24 Mcgill University The effect of receptor protein tyrosine phosphatase sigma (rptp-$g(s)) on neural axon regeneration and synapse modification
US7829087B2 (en) * 2001-07-09 2010-11-09 Elan Pharmaceuticals, Inc. Methods of treating cognitive impairment
WO2008157425A2 (en) * 2007-06-14 2008-12-24 The Regents Of The University Of California Compounds for inhibiting protein aggregation, and methods for making and using them
CA2764545C (en) * 2009-06-15 2019-05-14 Katholieke Universiteit Leuven, K.U.Leuven R&D Bace1 inhibitory antibodies
US20130171163A1 (en) * 2010-08-06 2013-07-04 Marschall Runge Inhibition of LAR Phosphatase to Enhance Therapeutic Angiogenesis
KR102160388B1 (ko) * 2012-03-19 2020-09-28 버크 인스티튜트 포 리서치 온 에이징 App 특이적 bace 억제제(asbi) 및 이의 용도
EP2841086B1 (en) * 2012-04-09 2018-09-26 Case Western Reserve University Compositions for use in treating neural injury by inhibiting the activity of lar family phosphatases
WO2017197253A2 (en) * 2016-05-12 2017-11-16 Ohio State Innovation Foundation Peptides and methods for treating neurodegenerative disorders

Also Published As

Publication number Publication date
EP3634979A4 (en) 2021-04-14
US20200093890A1 (en) 2020-03-26
CN110945011A (zh) 2020-03-31
EP3634979A1 (en) 2020-04-15
JP2020524132A (ja) 2020-08-13
WO2018226735A1 (en) 2018-12-13
AU2018281330A1 (en) 2019-12-19
CA3064479A1 (en) 2018-12-13

Similar Documents

Publication Publication Date Title
JP6920324B2 (ja) 神経細胞の損失予防及び再生の効能を有するペプチド及びこれを含む組成物
JP2018521014A (ja) ミスフォールドタンパク質の分解のための組成物及び方法
US11124553B2 (en) TDP-43 mitochondrial localization inhibitor for the treatment of neurogenerative disease
US20220104468A1 (en) Modulation of lc3-associated endocytosis pathway and genetically modified non-human animals as a model of neuroinflammation and neurodegeneration
JP2018525337A (ja) 軽度認知障害の処置のためのｊｎｋシグナル伝達経路の細胞透過性ペプチド阻害剤の新規使用
US20180170983A1 (en) New Use of Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway for the Treatment of Mild Cognitive Impairment
US10898550B2 (en) Compositions and methods of treating root avulsion injury
KR20200045446A (ko) 알츠하이머병의 치료를 위한 조성물 및 방법
WO2012144972A2 (en) Methods to inhibit neurodegeneration
Jakobsen et al. Functional Roles of Pigment Epithelium-Derived Factor in Retinal Degenerative and Vascular Disorders: A Scoping Review
US7790673B2 (en) Methods and compositions relating to cystatin C
KR102772298B1 (ko) 미엘린 장애의 치료를 위한 조성물 및 방법
US20140314790A1 (en) Caspase 9 inhibition and bri2 peptides for treating dementia
JPWO2007139120A1 (ja) アミロイドβクリアランス促進剤
KR101131512B1 (ko) 퇴행성신경질환 예방 또는 치료용 약제학적 조성물
EP4471054A2 (en) C-terminal fragment of apolipoprotein e and application thereof in inhibiting ?-secretase activity
JP5939528B2 (ja) カルモジュリン様皮膚タンパク質を有効成分として含む医薬組成物
KR20130003243A (ko) 세포침투 효율이 향상된 ｐｒａｓ40 융합단백질

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20191217

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210601

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230728

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240103

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20230728

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I